FIELD: pharmacology.
SUBSTANCE: invention relates to RTN prodrugs, pharmaceutical compositions containing such RTN prodrugs, and their use for the treatment of hypoparathyroidism.
EFFECT: effective treatment of hypoparathyroidism.
22 cl, 34 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LIQUID PHARMACEUTICAL FORMULATIONS OF PTH CONJUGATES | 2020 |
|
RU2817015C2 |
| METHOD OF TREATING OR CONTROL OF HYPOPARATHYROIDUS USING PARATHROOID HORMONE (PTH) CONJUGATE | 2019 |
|
RU2806753C2 |
| DOSAGE MODE OF PTH COMPOUND OF CONTROLLED RELEASE | 2017 |
|
RU2777357C2 |
| CONTROLLED RELEASE COMBINATION THERAPY WITH CNP AGONISTS | 2017 |
|
RU2768747C2 |
| CNP PRODRUGS | 2016 |
|
RU2824988C1 |
| PTH COMPOUNDS WITH LOW PEAK-TO-MINIMUM RATIOS | 2017 |
|
RU2766959C2 |
| NOVEL POLYMER hGH PRODRUGS | 2015 |
|
RU2718664C2 |
| IL-2 CONJUGATES | 2019 |
|
RU2809259C2 |
| STABLE LOCAL DRUG LEVELS FOR INNATE IMMUNITY AGONISTS | 2020 |
|
RU2817710C2 |
| BENZAZEPINE COMPOUNDS, CONJUGATES AND THEIR USE | 2018 |
|
RU2780334C2 |
